Aktienanalyse zu Sellas Life Sciences Group Inc (SLS)SLSSellas Life Sciences Group Inc

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sellas Life Sciences Group Inc is a good buy right now, trading at $11.54 with a strong year-to-date change of +165.29% and a 1-year change of +494.85%. The upcoming Regal trial results are critical, as they could significantly impact the stock price, with analysts projecting a target price up to $35. However, investors should be cautious of the company's ongoing net losses, which are expected to reach -$9,605,000 in Q2 2026, indicating financial instability.